ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 15, 2022 | Post-IPO Debt | $175M | 1 | Hercules Capital | — | Detail |
Mar 3, 2021 | Series D | $157M | 2 | — | — | Detail |
Nov 24, 2020 | Series C | $93M | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jan 9, 2023
IntelGenX
|
Post-IPO Debt | $3M | Biotechnology | Yes |
Feb 1, 2022
IntelGenX
|
Post-IPO Debt | $3M | Biotechnology | Yes |
Mar 15, 2021
IntelGenX
|
Post-IPO Equity | $12.34M | Biotechnology | Yes |
Mar 15, 2021
IntelGenX
|
Post-IPO Debt | $2M | Biotechnology | Yes |
Apr 24, 2019
Innoplexus
|
Series C | — | Analytics | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |
Korify Capital | — | Series D |
Gaingels | — | Series D |